Author

L. Brunetti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1

Frequent Co-Authors

A. Gagliardi· 1 shared A. Guzman· 1 shared A. Marra· 1 shared A. Nunez· 1 shared A. Rezvan· 1 shared B. Bigerna· 1 shared B. Falini· 1 shared C. D. D. Cristobal· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Gagliardi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML

G. Pianigiani, A. Gagliardi, F. Mezzasoma, F. Rocchio, V. Tini, B. Bigerna, P. Sportoletti, S. Caruso, A. Marra, G. Spinozzi, S. Shacham, Y. Landesman, C. Quintarelli, F. Locatelli, M. P. Martelli, , L. Brunetti

This study shows that prolonged XPO1 inhibition is more effective than intermittent dosing in NPM1-mutated AML by achieving stable HOX downregulation and anti-leukemic activity.

bioRxiv · Dec 11, 2021 · PreprintCancer Biology

Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities

J. H. Rogers, R. Gupta, J. M. Reyes, M. Gundry, G. Medrano, A. Guzman, T. Song, C. Johnson, S. Barnes, C. D. D. Cristobal, L. Brunetti, M. A. Goodell, R. E. Rau

This study models IKZF1 lesions in B-ALL to show distinct chemosensitivity patterns and therapeutic vulnerabilities, identifying cytarabine sensitivity and JAK/STAT upregulation as potential targets.

bioRxiv · May 26, 2020Cancer Biology

CIS checkpoint deletion enhances the fitness of cord blood derived natural killer cells transduced with a chimeric antigen receptor

K. Rezvani, M. Daher, R. Basar, E. Gokdemir, N. Baran, N. Uprety, M. Mendt, L. Kerbauy, M. Hernandez Sanabria, N. Imahashi, A. Nunez, L. Li, M. Fathi, A. Rezvan, V. Mohanty, , Wei Inn

This paper combines CIS checkpoint deletion with CAR engineering in NK cells to enhance their metabolic fitness and anti-tumor activity in a lymphoma model.

bioRxiv · Mar 29, 2020 · PreprintImmunology